Real-world Evaluation of Healthcare Resource Use and Costs in elder patients with Nonvalvular Atrial Fibrillation Treated With Apixaban vs. Warfarin in the US: A Retrospective Study

Trial Profile

Real-world Evaluation of Healthcare Resource Use and Costs in elder patients with Nonvalvular Atrial Fibrillation Treated With Apixaban vs. Warfarin in the US: A Retrospective Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 May 2017

At a glance

  • Drugs Apixaban (Primary) ; Warfarin (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 May 2017 Results presented at the 2017 Annual Scientific Meeting of the American Geriatrics Society
    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top